Journal
THORACIC CANCER
Volume 13, Issue 17, Pages 2539-2541Publisher
WILEY
DOI: 10.1111/1759-7714.14580
Keywords
immune checkpoint inhibitor; PPLELC; primary pulmonary lymphoepithelioma-like carcinoma
Categories
Ask authors/readers for more resources
Here, we present a case report of a late-stage PPLELC patient who showed a favorable response to ICIs treatment, which is the first of its kind in patients with PD-L1 expression in advanced PPLELC.
Here, we report a case of metastatic Epstein-Barr virus (EBV)-related primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) in a young, nonsmoking female who responded well to treatment with two types of immune checkpoint inhibitors (ICIs). This is the first case report of a favorable outcome to ICIs in the late-line treatment of advanced PPLELC patients with programmed cell death-ligand 1 (PD-L1) expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available